CompletedNCT04814355
Celecoxib and brain inflammation in major depression
About this title
Read the official source — NCT04814355Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Stony BrookSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: August 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Stony Brook University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04814355
- Official title
Show the full official title
The Effect of Celecoxib on Neuroinflammation in MDD: PET Imaging of a Novel Treatment Target With [18F]FEPPA
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stony Brook
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stony Brook University, a university.
Did this study involve medication?
Yes. The study involved medication, including Celecoxib 400 mg.
Who was this study for?
Listed age limits: 18 years to 65 years.
